11 results
To evaluate the effect of baricitinib 4-mg QD and background standard-of-care therapy compared with placebo and background standard-of-care therapy on SLE disease activity.
To construct the utility surfaces of tapentadol and oxycodone.
PrimaryTo evaluate the long-term safety and tolerability of baricitinib in patients with SLE.
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
The objective of this study is to investigate the extent of respiratory depression at equi-analgesic dosages of tapentadol and oxycodone
The primary objective of the study is to determine whether baricitinib is superior to placebo in the treatment of patients with moderately to severely active rheumatoid arthritis (RA) despite methotrexate treatment (ie, inadequate response to…
The primary objective of the study is to determine whether baricitinib 4 mg QD is superior toplacebo in the treatment of patients with moderately to severely active RA who have had an inadequate response to a TNF inhibitor, despite ongoing treatment…
The main objective is to assess whether Bediol (containing THC and CBD) co-treatment will reduce opioid side effects in chronic pain patients. A secondary objective will be that Bediol is superior to oxycodone in the relief of chronic fibromyalgia…
The primary objective of this study is to assess the effects of CPPF, executed by Haermonics Flush, in comparison with standard care on clinically relevant endpoints, like re-explorations, in a population of cardiac surgery patients that have an…
Primary Objectives: * to establish - which is the best treatment, MTX or baricitinib, to ensure rapid symptom relief of recent onset UA, based on clinical and patient reported outcomes from baseline to 3 months. Secondary Objective: * to establish…
The primary objective is to test the hypothesis that baricitinib high dose level in combination with topical corticosteroids (TCS) or baricitinib medium dose level in combination with TCS is superior to placebo in combination with TCS in the…